Antihypertensive Duration of Action of Cilazapril in Patients with Mild to Moderate Essential Hypertension

I. Kobrin, P. Güntzel, R. Viskoper, E. Paran, R. Zimlichman

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The efficacy of cilazapril monotherapy was evaluated in 2 multicentre double-blind dose-response trials. After 4 weeks of a single-blind placebo run-in period, patients with uncomplicated mild to moderate essential hypertension and a sitting diastolic blood pressure of 100 to 115mm Hg, 24 hours after the last placebo dose (trough), were randomised to take either placebo or cilazapril 2.5mg or 5mg for 4 weeks (study 1, 86 patients) or 8 weeks (study 2, 78 patients). Sitting diastolic blood pressure was checked every 2 weeks at trough in both studies and at peak in study 2. The reductions in sitting diastolic blood pressure from baseline at trough, and the difference from placebo, were clinically and statistically significant for both cilazapril groups in the 2 studies. The reduction in blood pressure in both active treatment groups was similar, but the response rate with cilazapril 5mg was greater than that with 2.5mg. More than 50% of the peak effect was still present at trough for both cilazapril groups. It is concluded that both dosages of cilazapril are effective and reduce blood pressure compared with placebo over a 24-hour period.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
Issue number1
StatePublished - 1 Jan 1991
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Antihypertensive Duration of Action of Cilazapril in Patients with Mild to Moderate Essential Hypertension'. Together they form a unique fingerprint.

Cite this